The role of renin-angiotensin system modulation in the pathophysiology of neuropsychiatric disorders.

Authors

Akhil Sharma, Tanya Goel, Ashi Mannan, Vetriselvan Subramaniyan, Thakur Gurjeet Singh

Published in

Hormones and behavior. Volume 186. Pages 106003. Oct 02, 2026. Epub Oct 02, 2026.

Abstract

The renin-angiotensin system (RAS), traditionally recognized for cardiovascular and renal regulation, has emerged as a critical mechanistic player in neuropsychiatric pathophysiology. The brain possesses its own independent RAS with components located throughout limbic regions, cortical areas, and monoaminergic circuits that are essential for mood, cognition, and behavior. Within this framework, angiotensin II (Ang II), acts primarily through angiotensin II type 1 receptors (AT1Rs), orchestrates pathological cascades including nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX)-mediated oxidative stress and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB)-driven neuroinflammation which converge to disrupt synaptic plasticity, impair neurogenesis, compromise blood-brain barrier (BBB) integrity, and dysregulate hypothalamic-pituitary-adrenal axis (HPA) axis- all contributing to major depression, anxiety disorders, schizophrenia, and bipolar disorder. However, the brain also contains protective RAS pathways, including angiotensin II Type 2 receptors (AT2Rs) and the angiotensin-converting enzyme 2/ Angiotensin-(1-7)/ Mas receptor (ACE2/Ang-(1-7)/MasR) axis, which offer neuroprotective effects that counterbalance these damaging processes. Therefore, targeting the RAS may represent a paradigm shift in neuropsychiatric treatment, as medications that modulate this system- including angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs)- show significant promise by addressing the fundamental molecular mechanisms driving mental illness rather than merely managing symptoms. Ultimately, this approach bridges peripheral physiological dysregulation with central nervous system (CNS) dysfunction, offering a precision medicine strategy that targets the root biological causes of neuropsychiatric disorders and opens new therapeutic avenues for patients who may not respond adequately to conventional treatments.

PMID:
42826581
Bibliographic data and abstract were imported from PubMed on 03 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.